Global Unfractionated Heparin Market by Source (Bovine and Porcine), by Application (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Embolism, and Others), by End-User (Hospitals Clinics, Ambulatory Surgical Centers and Academic and Research Organizations) Forecast (2022-2028)

The global unfractionated heparin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Unfractionated heparin is a fast-acting blood thinner with antithrombin, a natural protein in the body to block clot formation. The rise in the prevalence of cardiovascular diseases is one of the major factors driving the growth of the global unfractionated heparin market. For instance, according to the data published by World Health Organization (WHO) in 2021, approximately 17.9 million mortalities occurred due to cardiovascular diseases (CVDs) out of which 85% were due to heart attacks and stroke and are considered as the leading cause of mortalities globally. Thus, the global burden of cardiovascular diseases is anticipated to drive the demand for the unfractionated heparin market.

Looking towards the demand of unfractionated heparin market, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, Fresenius Kabi AG had introduced two presentations of Heparin Sodium in ready-to-administer Freeflex IV bags. Heparin Sodium in sodium chloride injection at a concentration of 2 USP units per ml is indicated as an anticoagulant to maintain catheter patency. These single-dose infusions are available in two strengths -1,000 USP units in 0.9% sodium chloride 500ml infusion bag and 2,000 USP units in 0.9% sodium chloride 1,000ml infusion bag .

Further in February 2020, Opocrin has acquired the whole stock of Laboratori Derivati  Organici (LDO), a company specialing in the manufacture of active pharmaceuticals, especially heparin and heparinoids. The transaction was a part of Opocrin’s strategic development in the biological active pharmaceutical ingredients of animal origin market. The new group is expected to have three production sites in Italy and one in Mexico with a combined workforce of approximately 270 resources. Thus, such acquisitions coupled with product launches are anticipated to drive the global unfractionated heparin market throughout the forecast period

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Source
  • By Application
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Baxter International Inc, Dr. Reddys Laboratories Ltd., Pfizer Inc, and Hebei Changshan Biochemical Pharmaceutical Co, Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Unfractionated Heparin Market Report by Segment

By Source

• Bovine
• Porcine

By Application

• Deep Vein Thrombosis,
• Pulmonary embolism
• Arterial Embolism
• Others

By End-User

• Hospital
• Clinics
• Academic and Research Organizations
• Ambulatory Surgical Centers
• Others

Global Unfractionated Heparin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa